Safety Alerts & Recalls
What does this mean?
Doctors who care for patients with cancers such as multiple myeloma or mantle cell lymphoma will routinely perform tests to determine how well the kidney, liver, and other body systems are working before beginning chemotherapy. These pre-chemotherapy evaluations will help your doctor determine the proper dose of chemotherapy medication for you. With that said, if you are receiving VELCADE or any chemotherapy, it will be helpful to your doctor if you provide your complete medication list and medical history (especially if you have a history of liver problems) at each visit. You should also attend all of your follow up appointments with your doctor to evaluate how well the chemotherapy is working and to monitor for side effects and toxicities.
If you have any questions about this new safety information, please follow up with your doctor or other healthcare professional.
Change to Prescribing Information for VELCADE to Include Dosage Adjustment in Liver Impairment
Takeda Oncology and the FDA recently notified healthcare professionals about changes to the Prescribing Information for VELCADE. The updated prescribing information provides new safety information on dose adjustment for patients with moderate to severe liver injury or impairment. Exposure to bortezomib, the active ingredient in VELCADE, may be increased in patients with moderate to severe liver problems. These patients should be treated with VELCADE at reduced starting doses and closely monitored for serious side effects and toxicities.
VELCADE is a chemotherapy medication indicated for the treatment of patients with multiple myeloma. VELCADE also is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.
For more information, please visit: more information here